Consensus EPS · Q2 2026
$10.24
Consensus revenue · Q2 2026
$3.8B
Analysts
14
Expected report
Jul 30, 2026
What to watch
- Analyst ratings: Upgrades trending
Analyst consensus
Based on estimates from 14 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $3.5B | $3.8B | $4.2B |
| EPS | $7.64 | $10.24 | $12.33 |
| EBITDA | $1.6B | $1.7B | $1.8B |
| EBIT | $1.5B | $1.5B | $1.7B |
| Net income | $852.2M | $1.1B | $1.4B |
- Revenue$3.8B
- EPS$10.24
- EBITDA$1.7B
- EBIT$1.5B
- Net income$1.1B
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q1 2026 | $3.6B | $3.5B | +3.6% | $9.47 | $8.91 | +6.2% |
- Q1 2026+3.6%+6.2%
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
| Metric | Now | 30d ago | 60d ago | 90d ago | 30d Δ |
|---|---|---|---|---|---|
| Revenue | $3.8B | $3.8B | — | — | -0.3% |
| EPS | $10.36 | $10.85 | — | — | -4.6% |
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for Regeneron Pharmaceuticals (REGN) Q2 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 6 analysts.
- Low
- $641.00
- Consensus
- $823.39
- Median
- $839.50
- High
- $1,000.00
- Current
- $651.18
- Upside
- +26.4%
Upside calculated vs most recent trading price of $651.18.
Analyst ratings
Consensus: Buy — based on 49 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 9, 2026 | Piper Sandler | maintain | Overweight | Overweight |
| Jul 8, 2026 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Jul 7, 2026 | Truist Securities | maintain | Buy | Buy |
| Jul 7, 2026 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Jul 7, 2026 | Benchmark | upgrade | Hold | Buy |
| Jul 6, 2026 | HSBC | maintain | Buy | Buy |
| Jul 6, 2026 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| May 19, 2026 | Canaccord Genuity | maintain | Buy | Buy |
| May 18, 2026 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| May 18, 2026 | Truist Securities | maintain | Buy | Buy |
- Jul 9, 2026Piper SandlerOverweight
- Jul 8, 2026Morgan StanleyEqual Weight
- Jul 7, 2026Truist SecuritiesBuy
- Jul 7, 2026RBC CapitalSector Perform
- Jul 7, 2026BenchmarkBuy
- Jul 6, 2026HSBCBuy
- Jul 6, 2026Cantor FitzgeraldOverweight
- May 19, 2026Canaccord GenuityBuy
- May 18, 2026Wells FargoEqual Weight
- May 18, 2026Truist SecuritiesBuy
Frequently asked questions
Regeneron Pharmaceuticals (REGN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.